| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
In myositis, 5/6 (83%) patients treated at 4 billion cells per dose with at least three months of follow-up achieved moderate or major responses, as measured by the Total Improvement Score (TIS) in the Ntrust-2 study of NKX019, an invest... |
| 06 Nov 2026 |
8-K: Regulation FD Disclosure
SOUTH SAN FRANCISCO, Calif., November 6, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced ... |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Initial clinical data for NKX019 in idiopathic inflammatory myopathy (myositis) and systemic sclerosis (scleroderma) to be presented at ACR Convergence 2026 |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
Enrollment continues across all indications in Ntrust-1 and Ntrust-2 at the 4 billion cell dose level (12 billion cells in 3-dose cycle) |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The 2026 annual meeting of stockholders (the "Annual Meeting") of Nkarta, Inc. (the "Company") was held on June 10, 2026. The results of the voting at the Annual Meeting are set forth below. |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 |
| 26 Mar 2026 |
8-K: Other Events
On March 25, 2026, Nkarta, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Stifel, Nicolaus & Company, Incorporated (“Stifel”) with respect to an at-the-market offering program under which the Company may... |
| 25 Mar 2026 |
8-K: Results of Operations and Financial Condition
Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 for a total of 12 billion cells per cycle |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide versus partial B-cell depletion in patients receiving only cyclophosphamide |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition
Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025 |
| 06 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus |
| 14 May 2025 |
8-K: Results of Operations and Financial Condition
Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment |
| 26 Mar 2025 |
8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities +2 more
Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases |
| 07 Nov 2024 |
8-K: Results of Operations and Financial Condition
First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studies |
| 13 Aug 2024 |
8-K: Entry into a Material Definitive Agreement
Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitis |
| 16 Jul 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
SOUTH SAN FRANCISCO, Calif., July 16, 2024 -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will j... |
| 27 Jun 2024 |
8-K: Regulation FD Disclosure; Other Events
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications |
| 13 Jun 2024 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +2 more
Senior R&D leader brings extensive expertise in immunology, clinical development and translational science |
| 09 May 2024 |
8-K: Results of Operations and Financial Condition
Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024 |
| 28 Mar 2024 |
8-K: Other Events
Introductory. Nkarta, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the “Underwriters,” or, each, an “Underwriter”), an ag... |
Loading...